Use of force plate analysis to assess the analgesic effects of etodolac in horses with navicular syndrome

Kelly D. Symonds Department of Veterinary Clinical Sciences, Center for Veterinary Health Sciences, Oklahoma State University, Stillwater, OK 74078.

Search for other papers by Kelly D. Symonds in
Current site
Google Scholar
PubMed
Close
 DVM
,
Charles G. MacAllister Department of Veterinary Clinical Sciences, Center for Veterinary Health Sciences, Oklahoma State University, Stillwater, OK 74078.

Search for other papers by Charles G. MacAllister in
Current site
Google Scholar
PubMed
Close
 DVM
,
Ronald S. Erkert Department of Physiological Sciences, Center for Veterinary Health Sciences, Oklahoma State University, Stillwater, OK 74078.

Search for other papers by Ronald S. Erkert in
Current site
Google Scholar
PubMed
Close
 DVM
, and
Mark E. Payton Department of Statistics, College of Arts and Sciences, Oklahoma State University, Stillwater, OK 74078.

Search for other papers by Mark E. Payton in
Current site
Google Scholar
PubMed
Close
 PhD

Abstract

Objective—To evaluate the musculoskeletal analgesic effect of etodolac administered PO every 12 or 24 hours in chronically lame horses by use of force plate analysis.

Animals—22 horses with navicular syndrome.

Procedure—Horses received etodolac (23 mg/kg, PO, q 12 h; n = 7), etodolac (23 mg/kg, PO, q 24 h; 8), or corn syrup (20 mL, PO, q 24 h; control treatment; 7) for 3 days. Combined forelimb peak vertical ground reaction force (PVF) was measured via force plate analysis before the first treatment (baseline) and at 6, 12, 24, and 36 hours after the last treatment. Differences in mean PVF (mPVF) between baseline and subsequent measurements were analyzed (repeated-measures ANOVA) and evaluated for treatment and time effects and treatment-time interaction.

Results—Once- or twice-daily administration of etodolac resulted in significant increases in mPVF from baseline at 6, 12, and 24 hours after the last treatment, compared with the control treatment. There were no significant differences in mPVF between the etodolac treatment groups at any time point. In both etodolac treatment groups, there was a significant increase in mPVF from baseline at 6, 12, and 24 hours, compared with that at 36 hours. Etodolac-associated adverse effects were not detected.

Conclusions and Clinical Relevance—In horses with navicular syndrome, once-daily oral administration of 23 mg of etodolac/kg appears to provide effective analgesia for as long as 24 hours. Twice-daily administration of etodolac at this same dose does not appear to provide any additional analgesic efficacy or duration of effect.

Abstract

Objective—To evaluate the musculoskeletal analgesic effect of etodolac administered PO every 12 or 24 hours in chronically lame horses by use of force plate analysis.

Animals—22 horses with navicular syndrome.

Procedure—Horses received etodolac (23 mg/kg, PO, q 12 h; n = 7), etodolac (23 mg/kg, PO, q 24 h; 8), or corn syrup (20 mL, PO, q 24 h; control treatment; 7) for 3 days. Combined forelimb peak vertical ground reaction force (PVF) was measured via force plate analysis before the first treatment (baseline) and at 6, 12, 24, and 36 hours after the last treatment. Differences in mean PVF (mPVF) between baseline and subsequent measurements were analyzed (repeated-measures ANOVA) and evaluated for treatment and time effects and treatment-time interaction.

Results—Once- or twice-daily administration of etodolac resulted in significant increases in mPVF from baseline at 6, 12, and 24 hours after the last treatment, compared with the control treatment. There were no significant differences in mPVF between the etodolac treatment groups at any time point. In both etodolac treatment groups, there was a significant increase in mPVF from baseline at 6, 12, and 24 hours, compared with that at 36 hours. Etodolac-associated adverse effects were not detected.

Conclusions and Clinical Relevance—In horses with navicular syndrome, once-daily oral administration of 23 mg of etodolac/kg appears to provide effective analgesia for as long as 24 hours. Twice-daily administration of etodolac at this same dose does not appear to provide any additional analgesic efficacy or duration of effect.

Contributor Notes

Dr. Symond's present address is 2421 W Mt Comfort Rd, Fayetteville, AR 72704.

Dr. Symonds conducted this study during the 3rd year of her professional program in the College of Veterinary Medicine as part of the NIH summer research training program.

The authors thank Fort Dodge Animal Health for provision of etodolac and Carl Gedon, Clint Stubblefield, Sabrina Cummings, and Amanda Skogen for technical assistance.

Dr. MacAllister.
  • 1

    USDA. APHIS info sheet: national economic cost of equine lameness, colic, and equine protozoal myeloencephalitis (EPM) in the United States. Washington, DC: USDA, Animal and Plant Health Inspection Service, 2001.

    • Search Google Scholar
    • Export Citation
  • 2

    McIlwraith CW, Frisbie DD, Kawcak CE. Nonsteroidal antiinflammatory drugs, in Proceedings. 47th Annu Meet Am Assoc Equine Pract 2001; 182187.

    • Search Google Scholar
    • Export Citation
  • 3

    Collins LG, Tyler DE. Phenylbutazone toxicosis in the horse: a clinical study. J Am Vet Med Assoc 1984; 184: 699703.

  • 4

    MacAllister CG, Morgan SJ, Borne AT, et al. Comparison of adverse effects of phenylbutazone, flunixin meglumine, and ketoprofen in horses. J Am Vet Med Assoc 1993; 202: 7177.

    • Search Google Scholar
    • Export Citation
  • 5

    Johnston SA, Fox SM. Mechanisms of action of anti-inflammatory medications used for the treatment of osteoarthritis. J Am Vet Med Assoc 1997; 210: 14861492.

    • Search Google Scholar
    • Export Citation
  • 6

    Tomlinson JE, Blikslager AT. Role of nonsteroidal antiinflammatory drugs in gastrointestinal tract injury and repair. J Am Vet Med Assoc 2003; 222: 946951.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7

    Schnitzer TJ, Constantine G. Etodolac (lodine) in the treatment of osteoarthritis: recent studies. J Rheumatol Suppl 1997; 47: 2331.

    • Search Google Scholar
    • Export Citation
  • 8

    Johnston SA, Budsberg SC. Nonsteroidal anti-inflammatory drugs and corticosteroids for the management of canine osteoarthritis. Vet Clin North Am Small Anim Pract 1997; 27: 841862.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9

    Glaser K, Sung ML, O'Neill K, et al. Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1. Eur J Pharmacol 1995; 281: 107111.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10

    Wilson JE, Chandrasekharan NV, Westover KD, et al. Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal antiinflammatory drugs. Am J Vet Res 2004; 65: 810818.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11

    Campbell NB, Blikslager AT. The role of cyclooxygenase inhibitors in repair of ischaemic-injured jejunal mucosa in the horse. Equine Vet J Suppl 2000; 32: 5964.

    • Search Google Scholar
    • Export Citation
  • 12

    Campbell NB, Jones SL, Blikslager AT. The effects of cyclooxygenase inhibitors on bile-injured and normal equine colon. Equine Vet J 2002; 34: 493498.

    • Search Google Scholar
    • Export Citation
  • 13

    Van Hoogmoed LM, Snyder JR, Harmon FA. In vitro investigation of the effects of cyclooxygenase-2 inhibitors on contractile activity of the equine dorsal and ventral colon. Am J Vet Res 2002; 63: 14961500.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 14

    Morton AJ, Campbell NB, Gayle JM, et al. Preferential and non-selective cyclooxygenase inhibitors reduce inflammation during lipopolysaccharide-induced synovitis. Res Vet Sci 2005; 78: 189192.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 15

    Stashak T. Navicular syndrome (navicular disease).. In: White NA, Moore JN, eds. Current techniques in equine surgery and lameness. 2nd ed. Philadelphia: WB Saunders Co, 1998; 537544.

    • Search Google Scholar
    • Export Citation
  • 16

    Keegan KG, Wilson DA, Wilson DJ, et al. Evaluation of mild lameness in horses trotting on a treadmill by clinicians and interns or residents and correlation of their assessments with kinematic gait analysis. Am J Vet Res 1998; 59: 13701377.

    • Search Google Scholar
    • Export Citation
  • 17

    Barr ARS, Dow SM, Goodship AE. Parameters of forelimb ground reaction force in 48 normal ponies. Vet Rec 1995; 136: 283286.

  • 18

    McLaughlin RM, Gaughan EM, Roush JK, et al. Effects of subject velocity on ground reaction force measurements and stance times in clinically normal horses at the walk and trot. Am J Vet Res 1996; 57: 711.

    • Search Google Scholar
    • Export Citation
  • 19

    Merkens HW, Schamhardt HC. Evaluation of equine locomotion during different degrees of experimentally induced lameness. I: lameness model and quantification of ground reaction force patterns of the limbs. Equine Vet J Suppl 1988; 6: 99106.

    • Search Google Scholar
    • Export Citation
  • 20

    Merkens HW, Schamhardt HC. Evaluation of equine locomotion during different degrees of experimentally induced lameness. II: Distribution of ground reaction force patterns of concurrently loaded limbs. Equine Vet J Suppl 1988; 6: 107112.

    • Search Google Scholar
    • Export Citation
  • 21

    Merkens HW, Schamhardt HC, van Osch GJVM, et al. Ground reaction force patterns of Dutch Warmblood horses at normal trot. Equine Vet J 1993; 25: 134137.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 22

    Merkens HW, Schamhardt HC, van Osch GJVM, et al. Ground reaction force patterns of Dutch Warmbloods at the canter. Am J Vet Res 1993; 54: 670674.

    • Search Google Scholar
    • Export Citation
  • 23

    Morris EA, Seeherman HJ. Redistribution of ground reaction forces in experimentally induced equine carpal lameness. Equine Exerc Physiol 1987; 2: 553563.

    • Search Google Scholar
    • Export Citation
  • 24

    Schamhardt HC, Merkens HW. Quantification of equine ground reaction force patterns. J Biomech 1987; 20: 443446.

  • 25

    Erkert RS, MacAllister CG, Payton ME, et al. Use of force plate analysis to compare the analgesic effects of intravenous administration of phenylbutazone and flunixin meglumine in horses with navicular syndrome. Am J Vet Res 2005; 66: 284288.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 26

    Hu HH, MacAllister CG, Payton ME, et al. Evaluation of the analgesic effects of phenylbutazone administered at a high or low dosage in horses with chronic lameness. J Am Vet Med Assoc 2005; 226: 414417.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 27

    MacAllister CG. Force plate analysis for the evaluation of NSAIDs in chronically lame horses, in Proceedings. 21st Annu Forum Am Coll Vet Intern Med 2003; 162163.

    • Search Google Scholar
    • Export Citation
  • 28

    Blikslager AT, Campbell NB, Morton AJ. Alternative COX-2 inhibitors for management of pain in horses, in Proceedings. 20th Annu Forum Am Coll Vet Intern Med 2002; 214216.

    • Search Google Scholar
    • Export Citation
  • 29

    American Association of Equine Practitioners. Definition and classification of lameness.. In: Guide for veterinary service and judging of equestrian events. 4th ed. Lexington, Ky: American Association of Equine Practitioners, 1991; 19.

    • Search Google Scholar
    • Export Citation
  • 30

    Lees P, Higgins AJ. Flunixin inhibits prostaglandin E2 production in equine inflammation. Res Vet Sci 1984; 37: 347349.

  • 31

    Lees P, Taylor JB, Maitho TE, et al. Metabolism, excretion, pharmacokinetics and tissue residues of phenylbutazone in the horse. Cornell Vet 1987; 77: 192211.

    • Search Google Scholar
    • Export Citation
  • 32

    Toutain PL, Autefage A, Legrand C, et al. Plasma concentrations and therapeutic efficacy of phenylbutazone and flunixin meglumine in the horse: pharmacokinetic/pharmacodynamic modeling. J Vet Pharmacol Ther 1994; 17: 459469.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 33

    Giuliano F, Ferraz JG, Pereira R, et al. Cyclooxygenase selectivity of non-steroid anti-inflammatory drugs in humans: ex vivo evaluation. Eur J Pharmacol 2001; 426: 95103.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 34

    Ricketts AP, Lundy KM, Seibel SB. Evaluation of selective inhibition of canine cyclooxygenase 1 and 2 by carprofen and other nonsteroidal anti-inflammatory drugs. Am J Vet Res 1998; 59: 14411446.

    • Search Google Scholar
    • Export Citation
  • 35

    Koupai-Abyazani MR, Esaw B, Laviolette B. Etodolac in equine urine and serum: determination by high-performance liquid chromatography with ultraviolet detection, confirmation, and metabolite identification by atmospheric pressure ionization mass spectrometry. J Anal Toxicol 1999; 23: 200209.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 36

    Tomlinson JE, Wilder BO, Young KM, et al. Effects of flunixin meglumine or etodolac treatment on mucosal recovery of equine jejunum after ischemia. Am J Vet Res 2004; 65: 761769.

    • Crossref
    • Search Google Scholar
    • Export Citation

Advertisement